Global Bisphosphonate Drug Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Bisphosphonate Drug Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Bisphosphonates are drugs that inhibit mineralization or resorption of the bone by blocking the action of osteoclasts. Bisphosphonates are enzyme-resistant analogues of pyrophosphate, which normally inhibits mineralization in the bone. Their effect is dose dependent and they reduce the turnover of bone by inhibiting recruitment and promoting apoptosis of osteoclasts. Bisphosphonates are used to treat postmenopausal and glucocorticoid induced osteoporosis, Paget's disease of bone and malignant hypercalcemia.

Market Overview:

The latest research study on the global Bisphosphonate Drug market finds that the global Bisphosphonate Drug market reached a value of USD 4091.93 million in 2022. It’s expected that the market will achieve USD 5273.91 million by 2028, exhibiting a CAGR of 4.32% during the forecast period.

Bisphosphonate Drug Growth Drivers

Almost every country in the world is experiencing an increase in the number and proportion of the elderly in its population. According to the data of world population prospects: 2019 revision, by 2050, one sixth of the people in the world will be over 65 years old (16%), which is higher than one tenth (9%) in 2019. By 2050, a quarter of the population living in Europe and North America will be aged 65 or above. In 2018, the number of people aged 65 and over in the world exceeded that of children under 5 for the first time. The number of people aged 80 or above is expected to triple, from 143 million in 2019 to 426 million in 2050.
Bone loss occurs when more bone is resorbed than formed by the body. Bone formation continues until peak bone mass (maximum solidness and strength) is reached. Bone mass, or bone density, peaks around age 30. After age 30, bone resorption slowly begins to outpace new bone formation. This can lead to bone loss. Bone loss is most rapid in women in the first few years after menopause but can continue into old age. Bisphosphonate drugs can slow bone loss. Their goal is to break down old bone and slow down its active osteoclasts, thereby reducing bone breakdown.
The aging of the population will become an important driving force to promote the growth of the demand in the Bisphosphonate Drug market, and people's demand for drugs is constantly increasing.
Osteoporosis is a serious disease that affects millions of people around the world. Without prevention or treatment, osteoporosis can develop without pain or symptoms until a fracture is broken. Paget's disease of bone is a chronic disease of the skeleton. Paget's disease most often affects older people, occurring in approximately 2 to 3% of the population over the age of 55. Prostate cancer is the most common cancer in men in the United States and the second leading cause of cancer death in men. One in seven men will be diagnosed with prostate cancer in their lifetime.
Bisphosphonates are used to reduce the risk of hip and spinal fractures in osteoporosis; Treat Paget's disease of bone; Preventing or reducing bone problems, including pain relief for some men with advanced prostate cancer. The increasing number of patients with various diseases will drive the demand of Bisphosphonate Drug industry.

Region Overview:

North America had the highest growth rate of all regions.

Company Overview:

The top three companies are Teva Pharmaceuticals, Novartis, AbbVie, with the revenue market share of 6.07%, 5.03% and 4.90% in 2021.

Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.

Novartis International AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world.

Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA).

Segmentation Overview:

By type, Alendronate segment accounted for the largest share of market in 2021.

Application Overview:

By application, the Postmenopausal Osteoporosis segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Bisphosphonate Drug market covered in Chapter 3:

Teva Pharmaceuticals
Apotex Corp
Roche
Aurobindo Pharma
Organon & Co.
CIPLA
Sun Pharma
Novartis
Viatris Inc.
AbbVie

In Chapter 4 and Chapter 14.2, on the basis of types, the Bisphosphonate Drug market from 2018 to 2029 is primarily split into:

Alendronate
Risedronate
Zoledronic Acid
Other Bisphosphonate Drug

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Bisphosphonate Drug market from 2018 to 2029 covers:

Postmenopausal Osteoporosis
Men with Osteoporosis
Paget’s Disease
Bone Loss Caused by Cancer Treatment
Glucocorticoid-induced Osteoporosis

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)